Table 2.

Association between average total LSEQ score and delirium occurrence in the following 24 hours after controlling for age, baseline severity of illness and nocturnal dexmedetomidine exposure (predictive analysis)

Variable	24-hour periods where both LSEQ score and delirium assessment documented (n=387)		P value	Univariable analysis		Multivariable analysis
	24-hour periods with delirium (n=56)	24-hour periods without delirium (n=331)		OR (95% CI)	P value	OR (95% CI)	P value
LSEQ 10-domain average	5.7±1.1	5.4±1.1	0.11	1.24 (0.95 to 1.62)	0.110	1.20 (0.92 to 1.58)	0.18
Age (years)	67.4±9.3	63.1±11.2	0.007*	1.04 (1.01 to 1.07)	0.008*	1.03 (0.99 to 1.06)	0.06
APACHE-II score	26.1±7.1	23.3±4.2	0.001*	1.04 (1.01 to 1.08)	0.017*	1.02 (0.99 to 1.06)	0.21
Dexmedetomidine (vs placebo)	18 (32%)	183 (55%)	0.001*	0.38 (0.21 to 0.70)	0.002*	0.42 (0.23 to 0.77)	0.005*

*P≤0.05.

APACHE, Acute Physiology and Chronic Health Evaluation; LSEQ, Leeds Sleep Evaluation Questionnaire.